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Abstract: Background: D-dimer (DD) levels have been reported as a sensitive but non-specific indicator for deep vein 
thrombosis (DVT) and pulmonary embolism (PE). Few reports have examined perioperative DD levels in musculoskeletal 
tumor. 
Materials/Methods: Subjects comprised 77 patients who had undergone oncological resection of musculoskeletal tumor. 
DD levels were assessed preoperatively and on postoperative days 1 and 7. Multidetector-row computed tomography 
(MD-CT) was performed to detect DVT/PE for cases with DD level >10.0 μg/ml. 
Results: Mean preoperative DD level was 0.84 μg/ml. Significant elevation of postoperative DD levels was confirmed. 
DD levels were significantly changed by various clinical conditions, such as malignancy, age and prosthetic reconstruc-
tion. In 4 of 5 cases with postoperative DD levels >10.0 μg/ml, DVT/PE was detected.  
Conclusion: Activation of the coagulation system by surgery and heterogeneity of DD levels under various clinical condi-
tions in musculoskeletal tumor patients were suggested. 
INTRODUCTION 
  Activation of coagulation and fibrinolysis is known to be 
associated with various clinical conditions including malig-
nancy, trauma, surgery and inflammatory disease [1-4]. As 
such activation results in deep vein thrombosis (DVT) and 
pulmonary embolism (PE), comprehension of activation 
status is critical to managing patients with hypercoagulopa-
thy. 
  D-dimer (DD) is a degradation product of cross-linked 
fibrin blood clots and reflects fibrin concentration. DD levels 
are increased in patients with enhanced fibrin formation and 
have been reported as sensitive indicators for DVT/PE [1, 3-
5]. Orthopaedic surgery itself involves major risks for hyper-
coagulopathy [1, 6, 7]. In addition, preoperative plasma DD 
level correlates with tumor stage and prognosis for patients 
with malignancy [8-12]. 
  Despite the potential clinical significance, few reports 
have examined DD levels in patients with musculoskeletal 
tumor. The primary goal of this study was to interpret the 
basic movement of perioperative DD levels in musculoskele-
tal tumor patients. In terms of heterogeneity between pa-
tients, DD levels might reveal heterogeneity under diverse 
clinical conditions such as age, tumor origin, location, ma-
lignancy or application of prosthesis. The second purpose of 
this study was thus to analyze the effects of diverse clinical 
conditions on DD levels in musculoskeletal tumor patients. 
In addition, clinical data of DVT/PE cases in the present 
study was disclosed. 
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MATERIALS AND METHODS 
  Subjects comprised 77 consecutive patients (32 men, 45 
women) who underwent oncological resection of muscu-
loskeletal tumor between May 2006 and September 2007. Pa-
tients were excluded if the presence of any of the following 
was identified: pre-existing hypercoagulopathy; recent antico-
agulant therapy including prophylaxis of thromboembolic 
complications during the test period; trauma; inflammatory 
diseases; and other major surgery. Mean patient age was 45.0 
years (range, 11-83 years). Underlying pathology was bone 
tumor in 32 cases and soft tissue tumor in 45 cases. Tumor 
location was the lower extremity in 44 cases, the trunk in 22 
cases and the upper extremity in 11 cases. For prevention of 
DVT after surgery, elastic stockings and intermittent pneumatic 
compression were applied. DD levels were measured using a 
latex agglutination assay (STA Liatest
® D-Di performed on the 
STA-R
® coagulation analyzer; Roche Diagnostics AG, 
Rotkreuz, Switzerland). Based on the sensitivity of this assay, 
DD levels < 0.20 μg/ml were considered as 0.20 μg/ml. DD 
levels were assessed preoperatively and on postoperative days 
1 and 7. The impact of diverse clinical conditions including 
age, tumor origin, site, malignancy and prosthetic reconstruc-
tion on DD levels was analyzed. Multidirector-row computed 
tomography (MD-CT) was indicated for the detection of 
DVT/PE for cases with DD levels > 10.0 μg/ml in the postop-
erative period. Clinical profiles of DVT/PE patients were as-
sessed retrospectively. For statistical analysis, Mann-Whitney 
U-tests, Kruskal Wallis tests, Wilcoxon matched-pair signed-
rank tests, Spearman rank correlation and 
2 tests were used. 
Values of p < 0.05 were considered statistically significant. 
RESULTS 
  To analyze pre-existing background bias in samples for 
this study, correlations between each clinicopathological fac-D-Dimer of Bone and Soft Tissue Tumors  The Open Orthopaedics Journal, 2008, Volume 2    131 
tor (age, tumor origin, site and malignancy) were examined. 
Patients with malignant tumor were significantly older than 
patients with benign tumor (p=0.03, Mann-Whitney U-tests), 
but no other significant correlations were identified (
2 tests). 
  DD levels at each evaluation time point are summarized in 
Table 1. Mean preoperative DD level for all subjects was 0.84 
μg/ml. Compared to preoperative DD levels, DD levels were 
significantly elevated on both day 1 (p < 0.001, Wilcoxon 
matched-pair signed-rank test) and day 7 (p=0.008). Signifi-
cant correlations were confirmed between preoperative DD 
and postoperative DD levels on day 1 (p < 0.001, Spearman 
rank correlation) and day 7 (p < 0.001). 
  Significant positive correlations between age and DD lev-
els at each time point were confirmed (preoperative DD, p = 
0.0005; postoperative DD on day 1, p = 0.046; postoperative 
DD on day 7, p=0.01, Spearman rank correlation). DD levels 
at each time point did not differ according to tumor origin 
(Mann-Whitney U-test). Although DD levels tended to be 
elevated for trunk or lower extremity cases compared to upper 
extremity cases, differences were not significant (Kruskal 
Wallis test). Preoperative DD levels were significantly higher 
for malignant tumor than for benign tumor (p < 0.001, Mann-
Whitney U-test). Postoperative DD levels on day 1 (p < 0.001) 
and day 7 (p < 0.001) were also significantly higher with ma-
lignant tumor than with benign tumor. DD levels of patients 
with prosthetic reconstruction were significantly higher than 
those without prosthetic reconstruction at each evaluation time 
point. Due to the limited application of prosthetic reconstruc-
tion for malignant bone tumor cases, subclass analysis was 
performed on the malignant bone tumor group, showing a 
significant difference in DD level on postoperative day 7 
(p=0.02, Mann-Whitney U-test). 
 
  DD levels > 10.0 μg/ml were detected in 5 cases post-
operatively, and MD-CT was performed for these patients to 
detect DVT/PE. DVT was detected in 4 of 5 cases. Further-
more, PE was detected in 3 of these 4 cases with DVT. All 4 
cases with DVT/PE were silent, and all 4 patients were 
women. Mean age  of the 4 patients with DVT/PE was 65 
years (range, 58-79 years). All cases involved malignant tu-
mor (synovial sarcoma in the abdominal muscle, low-grade 
fibromyxoid sarcoma in the perineal region, undifferentiated 
high-grade pleomorphic sarcoma in the calf and osteosarcoma 
in the femur). For all cases, wide resection was performed. For 
the osteosarcoma case, prosthetic reconstruction was per-
formed. DVT/PE was successfully controlled using heparin 
and inferior vena cava filter insertion. 
DISCUSSION 
  To date, measurement of DD has gained a prominent role 
as a rapid, simple, non-invasive and inexpensive test for ruling 
out DVT [1, 5, 13]. DD assays are, however, known to show 
positive results in the presence of common conditions includ-
ing cancer, surgery, inflammatory disease and trauma [6, 10, 
14-19]. Recent reports have re-confirmed several common 
properties in the clinical application of DD: variations in base-
line levels under different conditions; non-specificity as a 
marker for DVT/PE; and controversial aspects in the estab-
lishment of cut-off values. A recent meta-analysis found that 
assay sensitivity and negative predictive value were frequently 
<90% and concluded that general use of DD assays as a stand-
alone test for the diagnosis of DVT was not warranted [20]. 
Another meta-analysis reported that the significance of DD 
levels in the diagnosis of DVT was the cost-effectiveness 
when used as a part of algorithms combined with Wells score 
and ultrasound tests [21]. 
 
Table 1.  D-dimer Levels in Musculoskeletal Tumor Patients 
 
Preoperative D-Dimer  
Level (g/ml) 
D-Dimer Level on  
Postoperative Day 1 (g/ml) 
D-Dimer Level on  
Postoperative Day 7 (g/ml)  Variables Number 
Mean Range  p  Mean Range  p  Mean  Range  p 
Total cases  77  0.84  0.20-4.91     1.44  0.20-9.98     1.70  0.20-17.30    
Tumor orgin                               
    Bone  32  1.01  0.20-4.91     1.63  0.20-5.92     1.73  0.20-6.95    
    Soft tissue  45  0.73  0.20-3.86  0.20 1.30  0.20-9.98  0.13 1.69  0.20-17.30  0.28 
Site                               
    Lower extremity  44  0.82  0.20-3.31     1.49  0.2-5.92     1.70  0..20-8.70    
    Trunk  22  1.04  0.20-4.91     1.70  0.32-9.98     2.28  0.20-17.30    
    Upper extremity  11  0.55  0.20-2.90  0.13 0.72  0.20-2.20  0.08 0.52  0.20-1.30 0.12 
Malignancy                               
    Benign  30  0.34  0.20-1.00     0.71  0.20-2.72     0.48  0.20-3.2    
    Malignant  47  1.17  0.20-4.91  <0.001  1.90 0.25-9.98  <0.001 2.47 0.20-17.30  <0.001 
Prosthesis reconstruction                               
    Yes  9  1.59  0.70-3.31     2.74  0.96-5.92     3.41  1.83-6.95    
    No  68  0.75  0.20-4.91  0.0005  1.27 0.20-9.98  0.002 1.47  0.20-17.30  0.0003 
(In malignant bone tumor cases)                           
    Yes  9  1.59  0.70-3.31     2.74  0.96-5.92     3.41  1.83-6.95    
    No  12  1.23  0.20-4.91  0.05 1.73  0.50-3.86  0.14 1.62  0.20-3.64 0.02 132    The Open Orthopaedics Journal, 2008, Volume 2  Morii et al. 
  Malignancy [16], chemotherapy [22], reconstruction by 
prosthesis, reconstruction by plastic surgery, lower extremity 
predilection, tourniquet application, long-term bed rest and stay 
in a chronic care facility all represent potential properties of 
musculoskeletal tumor patients that may lead to abnormalities 
of coagulation and fibrinolytic activation. Accordingly, patients 
with musculoskeletal tumor are at increased risk for DVT/PE. 
To date, however, few studies have examined DD levels in 
bone and soft tissue tumors [14, 22, 23]. The present investiga-
tion represents the first systemic study to describe perioperative 
DD levels in patients with musculoskeletal tumor. In accor-
dance with previous studies on surgery for other conditions, the 
present study showed an impact of oncological resection of 
musculoskeletal tumor on postoperative DD levels. 
  Heterogeneity in patient characteristics might be marked as 
a striking limitation in analyzing DD levels in musculoskeletal 
tumor. Diversity in age [12], resection and reconstruction pro-
cedures [3, 24, 25], tumor location [25] and malignancy [9-12, 
18] may influence DD levels and incidence of DVT/PE. The 
present study tried to analyze the impact of several clinicopa-
thological factors on DD levels. As expected, malignancy, age 
and prosthesis reconstruction proved to have some impact on 
DD levels, suggesting heterogeneous conditions in DD levels 
of musculoskeletal tumor patients. 
  An avoidable limitation of the present study was the retro-
spective design. The present study used DD levels < 10.0 
μg/ml as a negative predictor of DVT/PE according to the 
standard for joint surgery in our institute. Nevertheless, judg-
ing from possible differences in condition of the coagulation 
system between conventional joint disease and musculoskele-
tal tumor, cut-off values of DD as a predictive value might be 
reorganized for musculoskeletal tumor patients. Accordingly, 
prospective regimens regarding detection of DVT/PE using 
conventional imaging techniques should be considered. 
  In summary, we retrospectively described perioperative 
DD levels in 77 consecutive patients with musculoskeletal 
tumor. Significant activation of the coagulation system under 
malignant conditions or by surgical procedures in muscu-
loskeletal tumor patients was suggested. Prospective investiga-
tion should be considered to determine prevalence rates, cut-
off values and time course for DD levels in association with 
DVT/PE. 
REFERENCES 
[1]  Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005; 
365(9465): 1163-74. 
[2]  Siragusa S, Anastasio R, Giarratano A, et al. Managing cancer pa-
tients with acute venous thromboembolism: exploring safe alterna-
tives to hospitalisation. Exp Oncol 2004; 26(3): 192-5. 
[3]  So AK, Varisco PA, Kemkes-Matthes B, et al. Arthritis is linked to 
local and systemic activation of coagulation and fibrinolysis path-
ways. J Thromb Haemost 2003; 1(12): 2510-5. 
[4]  Wahl WL, Ahrns KS, Zajkowski PJ, et al. Normal D-dimer levels do 
not exclude thrombotic complications in trauma patients. Surgery 
2003; 134(4): 529-32. 
[5]  Wells PS. Advances in the diagnosis of venous thromboembolism. J 
Thromb Thrombolysis 2006; 21(1): 31-40. 
[6]  Maezawa K, Nozawa M, Aritomi K, Kubota M, Shitoto K, Kurosawa 
H. Changes of D-dimer after total hip arthroplasty in patients with 
and without intraoperative heparin. Arch Orthop Trauma Surg 2008; 
128(1): 37-40. 
[7]  White RH, Zhou H, Romano PS. Incidence of symptomatic venous 
thromboembolism after different elective or urgent surgical proce-
dures. Thromb Haemost 2003; 90(3): 446-55. 
[8]  Altiay G, Ciftci A, Demir M, et al. High plasma D-dimer level is 
associated with decreased survival in patients with lung cancer. Clin 
Oncol (R Coll Radiol) 2007; 19(7): 494-8. 
[9]  Antoniou D, Pavlakou G, Stathopoulos GP, et al. Predictive value of 
D-dimer plasma levels in response and progressive disease in patients 
with lung cancer. Lung Cancer 2006; 53(2): 205-10. 
[10]  Gadducci A, Baicchi U, Marrai R, Ferdeghini M, Bianchi R, Facchini 
V. Preoperative evaluation of D-dimer and CA 125 levels in differen-
tiating benign from malignant ovarian masses. Gynecol Oncol 1996; 
60(2): 197-202. 
[11]  Kilic M, Yoldas O, Keskek M, et al. Prognostic value of plasma D-
dimer levels in patients with colorectal cancer. Colorectal Dis 2008; 
10(3): 238-41. 
[12]  Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative 
plasma D-dimer level is associated with advanced tumor stage and 
short survival after curative resection in patients with colorectal can-
cer. Jpn J Clin Oncol 2001; 31(8): 388-94. 
[13]  Wells PS. Integrated strategies for the diagnosis of venous throm-
boembolism. J Thromb Haemost 2007; 5 (Suppl 1): 41-50. 
[14]  Benevenia J, Bibbo C, Patel DV, Grossman MG, Bahramipour PF, 
Pappas PJ. Inferior vena cava filters prevent pulmonary emboli in pa-
tients with metastatic pathologic fractures of the lower extremity. 
Clin Orthop Relat Res 2004; 426: 87-91. 
[15]  Boldt J, Huttner I, Suttner S, Kumle B, Piper SN, Berchthold G. 
Changes of haemostasis in patients undergoing major abdominal sur-
gery-is there a difference between elderly and younger patients? Br J 
Anaesth 2001; 87(3): 435-40. 
[16]  Johnson MJ, Walker ID, Sproule MW, Conkie J. Abnormal coagula-
tion and deep venous thrombosis in patients with advanced cancer. 
Clin Lab Haematol 1999; 21(1): 51-4. 
[17]  Mukubo Y, Kawamata M. Higher preoperative D-dimer value re-
mains high postoperatively in patients with rheumatoid arthritis com-
pared with those with osteoarthrosis. J Anesth 2006; 20(1): 51-3. 
[18]  Satoh T, Oki A, Uno K, et al. High incidence of silent venous throm-
boembolism before treatment in ovarian cancer. Br J Cancer 2007; 
97(8): 1053-7. 
[19]  Terao M, Ozaki T, Sato T. Diagnosis of deep vein thrombosis after 
operation for fracture of the proximal femur: comparative study of ul-
trasonography and venography. J Orthop Sci 2006; 11(2): 146-53. 
[20]  Heim SW, Schectman JM, Siadaty MS, Philbrick JT. D-dimer testing 
for deep venous thrombosis: a metaanalysis. Clin Chem 2004; 50(7): 
1136-47. 
[21]  Goodacre S, Sampson F, Stevenson M, et al. Measurement of the 
clinical and cost-effectiveness of non-invasive diagnostic testing 
strategies for deep vein thrombosis. Health Technol Assess 2006; 
10(15): 1-168. 
[22]  Osanai T, Tsuchiya T, Ogino T. Deep venous thrombosis during 
neoadjuvant chemotherapy in a patient with osteosarcoma: a case re-
port. J Orthop Sci 2004; 9(2): 182-5. 
[23]  Choong PF. Cardiopulmonary complications of intramedullary fixa-
tion of long bone metastases. Clin Orthop Relat Res 2003; (415 
Suppl): S245-53. 
[24]  Fujita S, Hirota S, Oda T, Kato Y, Tsukamoto Y, Fuji T. Deep ve-
nous thrombosis after total hip or total knee arthroplasty in patients in 
Japan. Clin Orthop Relat Res 2000; 375: 168-74. 
[25]  Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment 
of venous thromboembolism. International Consensus Statement 
(guidelines according to scientific evidence). Int Angiol 2006; 25(2): 
101-61. 
 
 
Received: June 3, 2008  Revised: July 4, 2008  Accepted: August 1, 2008 
 
© Morii et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-
nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 